Rewards, Risk in Cell Therapy

The cell therapy space has a lot of potential. There are companies within the space that are developing therapeutics to treat diseases that affect millions with no cure or proven treatment. Results have been surprisingly strong so far, although one must expect a few hiccups along the way.

One of those hiccups was with Pluristem Therapeutics (PSTI), a stock that rallied 300% in the two years prior to September 2012. It has declined more than 15% since June 4. The stock's loss is in response to news that one of its Phase 2 trials has been suspended. Apparently, one of the patients being treated for artery disease had a "serious allergic reaction." This is the first reported incident, and who knows whether or not it has anything to do with the company's PLX cells....605 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.